

# BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES: GLOBAL MARKETS



HLC106B  
December 2014

Usha Nagavarapu  
*Project Analyst*

ISBN: 1-62296-007-6



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR COMPLETING THE STUDY	2
SCOPE AND FORMAT	3
INTENDED AUDIENCE	3
METHODOLOGY	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2012-2019 (\$ MILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 SEER SUMMARY STAGE SYSTEM FOR BREAST CANCER</i>	12
CLASSIFICATION OF BREAST CANCER	12
Luminal A and Luminal B Types	13
HER2 Type	13
Basal Type	13
CAUSES, INCIDENCE AND RISK FACTORS	14
SYMPTOMS	15
BREAST CANCER EVALUATION TESTS	15
PATHOPHYSIOLOGY	16
TREATMENT	17
<i>TABLE 2 TYPES OF HORMONE THERAPY FOR BREAST CANCER</i>	17
Cancer Treatment: Local or Systemic	17
<i>TABLE 3 BREAST CANCER STAGES</i>	18
Prognosis after Treatment	18
Breast Cancer Treatment Guidelines	18
PREVENTION	19
Patients at High Risk for Breast Cancer	19
METASTATIC BREAST CANCER	19
CHAPTER 4 BREAST CANCER	22
LATEST DEVELOPMENTS	22
BREAST CANCER DIAGNOSTICS AND TRENDS	23
EARLY BREAST CANCER DETECTION	23
Imaging Tests	24
Mammography	24
Diagnostic Mammograms	24
Digital Mammograms	24

<b>TOPIC</b>	<b>PAGE NO.</b>
Usefulness of Mammography	25
Magnetic Resonance Imaging of the Breast	25
Breast Ultrasound	26
Ductal Lavage and Nipple Aspiration	26
Biopsy	26
Fine Needle Aspiration Biopsy	27
Core Needle Biopsy	27
Vacuum-Assisted Biopsies	27
Surgical (Open) Biopsy	28
Laboratory Examination	28
Grades of Breast Cancer	28
<b>TABLE 4 BREAST CANCER GRADES</b>	29
Types of Breast Cancer	29
Ductal Carcinoma In Situ	29
Invasive (or Infiltrating) Ductal Carcinoma	29
Invasive (or Infiltrating) Lobular Carcinoma	30
IMAGING TESTS TO DETERMINE IF BREAST CANCER HAS SPREAD	30
<b>TABLE 5 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD</b>	30
GENE EXPRESSION PROFILING	30
<b>TABLE 6 TESTS USED TO EVALUATE DIFFERENT GENE SETS FOR BREAST CANCER TREATMENT</b>	31
ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR STATUS	31
HER2/NEU STATUS	32
<b>TABLE 7 BIOPSY AND SURGICAL SAMPLE TESTING TECHNIQUES</b>	32
USEFULNESS OF TESTS	33
FUTURE OF BREAST CANCER DETECTION	33
DIAGNOSTIC TESTS AND THEIR VALUE IN BREAST CANCER TESTING	33
HER-2 Testing	33
<b>TABLE 8 HER2 TESTING AND VARIATIONS</b>	34
ER Testing	34
FISH Testing	35
Genomic Assay	36
Quantitative Fluorescence Testing	37
Mammostrat	37
NEED FOR BREAST CANCER SCREENING	38
OVERDIAGNOSIS	39
DIAGNOSIS AND TREATMENT REGIMEN	40
GUIDELINES FOR BREAST CANCER DETECTION	41
<b>TABLE 9 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN</b>	41
Changes in Breast Cancer Screening Recommendations	42
Changes to Breast Cancer Screening Guidelines	42
BREAST CANCER SCREENING GUIDELINES	43
USPSTF Guidelines	43
ACR/SBI Guidelines	44
American Cancer Society Guidelines for the Early Detection of Cancer	45
Mammogram Recommendations	45

<b>TOPIC</b>	<b>PAGE NO.</b>
MEDICATIONS FOR RISK REDUCTION OF PRIMARY BREAST CANCER IN WOMEN	45
Potential Harms of Medications for Breast Cancer Risk Reduction	47
CHAPTER 5 BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS	49
BIOMARKERS AND CANCER	49
BIOMARKERS AND BREAST CANCER	49
<i>TABLE 10 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (NO.%)</i>	50
<i>TABLE 11 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE</i>	51
PROGNOSTIC TESTS	51
HER2 Status	52
COMPANION DIAGNOSTICS	52
<i>TABLE 12 APPROVED COMPANION DIAGNOSTICS FOR BREAST CANCER</i>	52
PREDICTIVE DIAGNOSTICS	54
Predictive Safety Biomarkers	54
Commercialized Biomarker Tests	55
Biomarkers and Drug Therapy	57
TARGETED THERAPIES	57
INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS	58
OBSTACLES TO BIOMARKER DEVELOPMENT	58
MAJOR ISSUES AND CHALLENGES TO BIOMARKER DEVELOPMENT	58
BIOMARKER TYPES	59
Predictive Biomarkers	59
Tumor Interstitial Fluid Biomarkers	59
Other Biomarkers	60
PHARMACOGENOMICS	60
Pharmacogenomic Biomarkers on Drug Labels	60
Benefits of Pharmacogenomics	60
Pharmacogenomics Tests Currently in Use	61
Barriers to the Pharmacogenomics Progress	62
Biomarker Information on Drug Labels	62
<i>TABLE 13 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE</i>	63
<i>TABLE 14 CLINICALLY RELEVANT BIOMARKERS</i>	63
FDA GUIDANCE	64
APPROVED BIOMARKERS FOR COMPANION DIAGNOSTICS	64
Herceptin-Based Testing	65
Co-development of Drug Diagnostics	65
COMPANION DIAGNOSTICS AND REGULATORY ISSUES	66
REGULATORY APPROVAL PATHWAY FOR DIAGNOSTICS	67
FDA Route	67
CLIA-Based (Laboratory-Developed Tests) Route	67
CHOOSING A REGULATORY PATHWAY	68
Co-development Path	68
Issues and Barriers to Development	69
NEW CANCER DRUGS APPROVED IN 2014	70

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 15 FDA APPROVED CANCER DRUGS, 2014</i>	71
POST-LAUNCH EXPECTATIONS	72
Dako's EGFR Immunohistochemistry Assay	72
Role of Reimbursement Bodies	73
CONSIDERATIONS FOR NEW DRUG-DIAGNOSTIC PARTNERSHIPS	73
FDA-APPROVED COMPANION DIAGNOSTICS	74
Roche FISH DNA Probe for HER2/Neu	74
PathVysion HER2 DNA Probe Kit	74
Pathway Anti-HER2/Neu (4B5)	74
Dako EGFR PharmDx Kit	74
Dako C-Kit PharmDx	74
InSite HER2/Neu Kit	75
SPOT-Light HER2 CISH Kit	75
Bond Oracle HER2 IHC System	75
HER2 CISH PharmDx Kit	75
INFORM HER2 Dual ISH DNA Probe Cocktail	75
Vysis ALK Break Apart FISH Probe Kit	76
cobas 4800 BRAF V600 Mutation Test	76
HercepTest	76
HER2 FISH PharmDx Kit	77
PROGNOSIS AND PHARMACOGENETICS TESTS	77
<i>TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION</i>	78
Breast Cancer MDx Platforms	78
<i>TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	78
Next-Generation Breast Cancer Tests	79
<i>TABLE 18 NEXT GENERATION BREAST CANCER TESTS</i>	80
Breast Cancer Early Detection/Screening Tests	81
Breast Cancer Risk Tests	82
Chemotherapy Response, Recurrence Probability and Subtyping Tests	83
NEXT STEPS	86
CHAPTER 6 BREAST CANCER PREVALENCE AND INCIDENCE RATES	88
CANCER INCIDENCE GLOBALLY	88
<i>TABLE 19 DIAGNOSED CASES OF CANCER EXCLUDING NON-MELANOMA SKIN CANCER, 2012 (NO./%)</i>	88
<i>TABLE 20 MOST COMMONLY DIAGNOSED CANCERS GLOBALLY, 2012 (MILLIONS/%)</i>	89
REGIONAL DIFFERENCES IN CANCER INCIDENCE	90
Incidence in Developed and Less Developed Countries	90
<i>TABLE 21 AGE STANDARDIZED CANCER RATE PER 100,000 PEOPLE IN DEVELOPED AND LESS DEVELOPED COUNTRIES, 2012</i>	91
CANCER TRENDS OVER TIME	92
CANCER PROJECTIONS TO 2030	93
BREAST CANCER GLOBALLY	93
GLOBAL BREAST CANCER STATISTICS	94
<i>TABLE 22 BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008 (THOUSANDS)</i>	95

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 1 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008 (THOUSANDS)</i>	96
GEOGRAPHIC VARIATION IN BREAST CANCER RATES	96
<i>TABLE 23 BREAST CANCER INCIDENCE BY COUNTRY, 2012</i>	97
<i>TABLE 24 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019</i>	99
<i>FIGURE 2 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019 (NO. OF CASES)</i>	99
GLOBAL INCIDENCE OF BREAST CANCER	99
RISING BREAST CANCER RATES	100
<i>TABLE 25 NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 AND 2012</i>	102
Factors	102
BREAST CANCER INCIDENCE IN DEVELOPED COUNTRIES	103
<i>TABLE 26 ESTIMATED GLOBAL BREAST CANCER INCIDENCE RATES FOR ALL AGES, 2012</i>	104
<i>TABLE 27 POTENTIAL REDUCTION IN DEATHS DUE TO BREAST CANCER FROM EARLY DETECTION, U.K. AND U.S. (CASES PER DAY)</i>	104
United States	105
Trends in Incidence and Mortality	106
U.S. Breast Cancer Incidence	107
<i>TABLE 28 U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019 (NO.)</i>	108
<i>FIGURE 3 U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019 (NO.)</i>	108
Historical Data	109
<i>TABLE 29 U.S. NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011 (THOUSANDS)</i>	109
2012 Breast Cancer Estimates	110
<i>TABLE 30 U.S. ESTIMATED BREAST CANCER INCIDENCE AND DEATHS, 2012 (THOUSANDS)</i>	110
Breast Cancer in Men	110
<i>TABLE 31 COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN IN THE U.S., 2012</i>	110
U.S. Breast Cancer Statistics and Race	111
Breast Cancer in Caucasian Women	111
Breast Cancer in African American Women	111
Breast Cancer in Ashkenazi Jewish Women	112
Breast Cancer in Women of Other Races	112
<i>TABLE 32 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY BY RACE, 2006-2010 (INCIDENCE PER 100,000)</i>	113
Breast Cancer in Asian American Women	113
<i>TABLE 33 U.S. ESTIMATED BREAST CANCER INCIDENCE (2004-2008) AND MORTALITY (2003-2007) FOR ASIAN WOMEN (PER 100,000)</i>	113
Breast Cancer in Hispanic/Latina Women	114
<i>TABLE 34 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY FOR HISPANIC/LATINA WOMEN, 2006-2010 (PER 100,000)</i>	114
Breast Cancer in Native American Women	114
<i>TABLE 35 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY IN NATIVE AMERICAN WOMEN COMPARED WITH OTHER RACES, 2006-2010 (PER 100,000)</i>	115
Recurrence and Metastatic Breast Cancer	115
Age and Breast Cancer	115

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 36 BREAST CANCER RISK BY AGE</i>	116
In Situ Breast Cancer	116
Invasive Breast Cancer	116
Incidence Trends by Race and Tumor Size	117
Incidence and Mortality Trends for Male Breast Cancer	117
Factors Influencing Breast Cancer Survival	117
<i>TABLE 37 RELATIVE CANCER SURVIVAL IN WOMEN IN THE U.S. (%)</i>	118
Obesity, Physical Activity and Diet	118
Historical Facts	118
Canada	119
Breast Cancer Facts	120
<i>TABLE 38 ESTIMATED CANADIAN BREAST CANCER STATISTICS, 2014</i>	120
<i>TABLE 39 CANADIAN ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010</i>	121
Europe	121
<i>TABLE 40 ESTIMATED NEW BREAST CANCER CASES, DEATHS FROM CANCER AND AGE-STANDARDIZED RATES PER 100,000 IN EUROPE, 2012 (THOUSANDS)</i>	122
United Kingdom and Ireland	122
<i>TABLE 41 BREAST CANCER STATISTICS IN THE U.K. AND IRELAND</i>	123
Key Breast Cancer Statistics	123
<i>TABLE 42 U.K. AGE STANDARDIZED BREAST CANCER INCIDENCE RATES, 2011 (PER 100,000)</i>	124
<i>TABLE 43 U.K. AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES, 2008 (PER 100,000.)</i>	125
<i>TABLE 44 ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K., 2008-2019</i>	126
<i>FIGURE 4 ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K., 2008-2019 (THOUSANDS)</i>	126
Germany	127
<i>TABLE 45 GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019</i>	127
<i>FIGURE 5 GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019</i>	127
Australia	128
<i>TABLE 46 PROJECTED NEW CASES OF BREAST CANCER IN AUSTRALIA AND NEW ZEALAND, 2012</i>	128
BREAST CANCER INCIDENCE IN DEVELOPING COUNTRIES	128
Asia	128
<i>TABLE 47 ASIAN ESTIMATED BREAST CANCER INCIDENCE, 2012</i>	129
China	129
<i>TABLE 48 CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019</i>	130
<i>FIGURE 6 CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019</i>	130
India	131
<i>TABLE 49 INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-2019 (THOUSANDS)</i>	133
<i>FIGURE 7 INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-(NO. OF CASES)2019</i>	133
Japan	134
<i>TABLE 50 JAPANESE ESTIMATED BREAST CANCER INCIDENCE, 2010-2012 (THOUSANDS)</i>	134
BREAST CANCER INCIDENCE IN LESS DEVELOPED COUNTRIES	134
<i>TABLE 51 FIVE-YEAR SURVIVAL RATES FOR BREAST CANCER (%)</i>	135

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 52 SELECTED BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE (%)</i>	136
Breast Cancer in Low-Income Countries	136
BREAST CANCER INCIDENCE IN MIDDLE-INCOME COUNTRIES	136
Mexico	137
Africa	138
Arabic Region	138
OTHER FACTORS	138
Tumor Characteristics	138
Environmental Factors and Breast Cancer Risk	139
SURVIVAL BY DISEASE STAGE	139
<i>TABLE 53 U.S. PERCENTAGE OF BREAST CANCER CASES AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2004-2010 (%)</i>	139
FAMILY HISTORY OF BREAST CANCER AND GENETIC PREDISPOSITION	140
CONCLUSIONS	140
CHAPTER 7 BREAST CANCER DRUGS AND MARKET TRENDS	143
CLINICAL DIAGNOSIS AND MANAGEMENT	143
<i>TABLE 54 ONCOLOGY DRUGS APPROVED BY THE FDA, 2014</i>	143
<i>TABLE 55 ONCOLOGY DRUGS APPROVED BY THE FDA, 2013</i>	143
<i>TABLE 56 ONCOLOGY DRUGS APPROVED BY THE FDA, 2012</i>	144
<i>TABLE 57 ONCOLOGY DRUGS APPROVED BY THE FDA, 2011</i>	145
<i>TABLE 58 ONCOLOGY DRUGS APPROVED BY THE FDA, 2010</i>	145
CANCER DRUGS AND MARKET TRENDS	146
DIAGNOSTICS FOR CANCER DRUGS	147
Circulating Tumor Cells	148
Imaging Tests	148
Scintimammography or Molecular Breast Imaging	148
Tomosynthesis or 3-D Mammography	148
TYPES OF THERAPEUTIC TREATMENTS FOR BREAST CANCER	149
Local versus Systemic Therapy	149
Adjuvant and Neo-adjuvant Therapy	149
BREAST CANCER TREATMENT OPTIONS	149
FDA Approved Drugs to Treat Breast Cancer	150
<i>TABLE 59 DRUGS APPROVED TO TREAT BREAST CANCER</i>	151
Hormone Therapy	152
<i>TABLE 60 HORMONE THERAPY FOR BREAST CANCER</i>	153
<i>TABLE 61 AROMATASE INHIBITORS FOR TREATING BREAST CANCER</i>	153
Chemotherapy	153
<i>TABLE 62 CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER</i>	153
Drugs to Control Side Effects of Breast Cancer Treatment	154
Targeted Therapies for Breast Cancer	154
Herceptin (Trastuzumab)	154
Pertuzumab	155
Lapatinib	155
<i>TABLE 63 TARGETED THERAPEUTICS FOR BREAST CANCER</i>	155
Avastin	155
Afinitor	156
Everolimus	156



<b>TOPIC</b>	<b>PAGE NO.</b>
Kadcyla	157
Treatment for Breast Cancer with Low HER2 Expression	157
Trastuzumab for Women with HER2-Low Breast Cancer	157
NeuVax	158
Tamoxifen	159
Palbociclib	160
Emerging Therapies	160
Triple Negative Breast Cancer	160
Treatments for BRCA Mutation-Related Cancer	162
TARGETED CANCER DRUG MARKET	163
<i>TABLE 64 GLOBAL MARKET FOR TARGETED CANCER DRUGS, 2008-2019 (\$ MILLIONS)</i>	163
GLOBAL PHARMACEUTICAL MARKET	164
<i>TABLE 65 GLOBAL PHARMACEUTICAL SALES, THROUGH 2019 (\$ MILLIONS)</i>	165
<i>FIGURE 8 GLOBAL PHARMACEUTICAL SALES, 2010-2019 (\$ MILLIONS)</i>	165
CURRENT BREAST CANCER MARKET TRENDS	166
NEW DEVELOPMENTS IN THE BREAST CANCER TREATMENT MARKET	167
MARKET DYNAMICS	169
BREAST CANCER MARKET	169
<i>TABLE 66 BREAST CANCER THERAPY SALES, THROUGH 2019 (\$ MILLIONS)</i>	170
<i>FIGURE 9 BREAST CANCER THERAPY SALES, 2010-2019 (\$ MILLIONS)</i>	170
<i>TABLE 67 BREAST CANCER DRUG MARKET, 2014 AND 2019 (\$ MILLIONS)</i>	170
<i>FIGURE 10 BREAST CANCER DRUG MARKET, 2014 AND 2019 (\$ MILLIONS)</i>	170
AROMATASE INHIBITORS	171
TARGETED THERAPIES	171
Perjeta	172
<i>TABLE 68 PERJETA DRUG SALES, 2012-2014 (\$ THOUSANDS)</i>	172
Kadcyla	173
<i>TABLE 69 KADCYLA DRUG SALES, 2013 AND 2014 (\$ THOUSANDS)</i>	173
Herceptin	173
<i>TABLE 70 HERCEPTIN DRUG SALES, 2012-2014 (\$ THOUSANDS)</i>	173
<i>TABLE 71 BREAST CANCER TARGETED THERAPIES, 2010-2014 (\$ MILLIONS)</i>	174
Tykerb	174
PATENTS ON TARGETED THERAPIES	175
SALES OF HERCEPTIN, XELODA, PERJETA AND KADCYLA	175
<i>TABLE 72 ROCHE PHARMACEUTICALS DIVISION SALES, 2012-2013 (\$ MILLIONS)</i>	175
<i>TABLE 73 ROCHE SALES COMPARED WITH THE GLOBAL MARKET, 2010 (\$ MILLIONS/%)</i>	176
<i>TABLE 74 XELODA SALES, 2010 AND 2011 (\$ MILLIONS)</i>	176
<i>TABLE 75 ROCHE SALES VERSUS THE GLOBAL MARKET, 2011 (\$ MILLIONS/%)</i>	177
OTHER MEDICINES FOR BREAST CANCER	178
<i>TABLE 76 EXPECTED SALES FOR PERTUZUMAB, 2016</i>	178
Perjeta/Pertuzumab	178
REGIONAL BREAST CANCER MARKETS	179
Australian Breast Cancer Treatment Market	179
<i>TABLE 77 AUSTRALIA: CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)</i>	179
<i>TABLE 78 AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)</i>	180

TOPIC	PAGE NO.
Indian Breast Cancer Treatment Market	180
China	181
Europe	181
CONCLUSIONS	181
CHAPTER 8 BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET	184
PROJECTED CANCER COSTS	184
CANCER DRUG MARKET	184
BREAST CANCER DRUGS	185
<i>TABLE 79 BREAST CANCER MONOCLONAL ANTIBODY MARKET, 2014 AND 2019 (\$ MILLIONS)</i>	185
U.S. PERSONALIZED MEDICINE MARKET SIZE	186
COST OF BREAST CANCER CARE	186
<i>TABLE 80 ANNUALIZED MEAN NET COST OF BREAST CANCER CARE, 2010 (\$ PER PATIENT)</i>	186
<i>TABLE 81 U.S. PREDICTIVE PERSONALIZED MEDICINE MARKET, 2013 AND 2019 (\$ MILLIONS)</i>	187
<i>FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2013 AND 2019 (\$ MILLIONS)</i>	187
<i>TABLE 82 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	188
<i>FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2011-2019 (\$ MILLIONS)</i>	188
PERSONALIZED MEDICINE AND ISSUES	189
FACTORS INFLUENCING MARKET GROWTH AND INDUSTRY SPECIFIC CHALLENGES	189
GLOBAL MOLECULAR DIAGNOSTICS MARKET	189
<i>TABLE 83 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	190
U.S. MOLECULAR-BASED CANCER DIAGNOSTICS MARKET	190
GLOBAL IN VITRO DIAGNOSTICS MARKET	191
<i>TABLE 84 GLOBAL IVD MARKET, THROUGH 2019 (\$ MILLIONS)</i>	192
BREAST CANCER TESTING MARKET	192
<i>TABLE 85 BREAST CANCER DIAGNOSTIC TESTS</i>	192
<i>TABLE 86 BREAST CANCER GENETIC TESTS</i>	196
NEXT-GENERATION CANCER DIAGNOSTICS	196
GLOBAL BREAST CANCER MARKET AND TRENDS	196
<i>TABLE 87 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2012-2019</i>	197
<i>TABLE 88 GLOBAL INCIDENCE OF ER-POSITIVE BREAST CANCER, 2012-2019</i>	198
BREAST IMAGING	198
Mammography Equipment	199
BREAST BIOPSY	200
BREAST CANCER AND MOLECULAR DIAGNOSTICS	202
COMPANION DIAGNOSTICS	202
PREDICTIVE TECHNOLOGY AND BREAST CANCER MARKET TRENDS	202
Tests for Breast Cancer Prognosis	203
HER2	203
Gene Expression Profiling Tests	203
IHC4 Test	204
<i>TABLE 89 BREAST CANCER DIAGNOSTIC TEST COSTS</i>	205

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 90 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)</i>	206
<i>FIGURE 13 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2012-2019 (\$ MILLIONS)</i>	206
IHC AND FISH-BASED TESTS MARKET	207
<i>TABLE 91 IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2019 (\$ MILLIONS)</i>	207
<i>FIGURE 14 IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2012-2019 (\$ MILLIONS)</i>	208
TISSUE-BASED IMMUNOHISTOCHEMISTRY MARKET	208
<i>TABLE 92 FDA-APPROVED COMMERCIAL IHC KITS</i>	208
HercepTest Kits	209
<i>TABLE 93 FDA-APPROVED FISH ANALYSIS TESTS</i>	210
KEY COMPANIES	211
ROCHE	211
<i>TABLE 94 ONCOLOGY BREAST CANCER DRUG SALES BY REGION, 2013 (\$ MILLIONS)</i>	212
<i>TABLE 95 ROCHE DIAGNOSTIC SALES, 2012 AND 2013 (\$ MILLIONS)</i>	213
<i>TABLE 96 ROCHE SALES BY DIVISION, 2010 (\$ MILLIONS)</i>	213
<i>TABLE 97 CURRENTLY MARKETED ROCHE COMPANION DIAGNOSTICS</i>	214
DAKO	214
GENOMIC ASSAYS	215
<i>TABLE 98 GENOMIC ASSAY MARKET LEADERS</i>	215
<i>TABLE 99 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019 (\$ MILLIONS)</i>	216
<i>FIGURE 15 GENOMIC TESTING MARKET FOR BREAST CANCER, 2012-2019 (\$ MILLIONS)</i>	216
GENOMIC HEALTH	217
Oncotype DX	217
<i>TABLE 100 ONCOTYPE DX SALES, THROUGH 2019 (\$ MILLIONS)</i>	218
AGENDIA	218
MammaPrint Assay	218
QUANTITATIVE FLUORESCENCE-BASED TESTS	220
CCC Diagnostics LLC	220
DirectHit Test Panel	220
<i>TABLE 101 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019 (\$ MILLIONS)</i>	220
<i>FIGURE 16 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2012-2019 (\$ MILLIONS)</i>	221
NanoString Technologies	223
Prosigna Assay	223
CONCLUSIONS	224
CHAPTER 9 COMPANY PROFILES	227
ABBOTT LABORATORIES	227
AETERNA ZENTARIS	228
AGENDIA	228
ALTHEADX	230
AMBERGEN INC.	230
ASTRAZENECA PLC	230

<b>TOPIC</b>	<b>PAGE NO.</b>
ATOSSA GENETICS INC.	231
BIOCON	231
BIOTIME	231
CCC DIAGNOSTICS LLC	232
CLARIENT	233
DAKO	234
EISAI INC.	234
EUTROPICS PHARMACEUTICALS	235
FLUXION BIOSCIENCES	235
GENENTECH	235
GENOMIC HEALTH	236
GLAXOSMITHKLINE	236
LIFE TECHNOLOGIES CORP.	237
MATRIX-BIO INC.	237
MDXHEALTH	238
MERCK AND CO. INC.	238
MYRIAD GENETICS	238
NANOSTRING TECHNOLOGIES	239
PFIZER	239
PHIGENIX	239
PROVISTADX LABORATORIES	240
PURDUE RESEARCH FOUNDATION	241
RUBICON GENOMICS	241
SANOFI S.A.	241
VENTANA MEDICAL SYSTEMS INC.	242
CHAPTER 10 DEVELOPMENTS AND COLLABORATIONS	244
CURRENT AND FUTURE DEVELOPMENTS	244
COMMERCIAL OPPORTUNITIES FOR CANCER BIOMARKER-BASED DIAGNOSTIC TESTS	244
NanoString Technologies	244
Roche	245
DISCOVERY	245
RECENT BREAST CANCER TEST APPROVALS	246
Provista	246
Matrix-Bio	246
Eutropics Laboratory	247
Ventana Medical Systems	247
BREAST CANCER TESTS	248
Oncotype DX	248
RECENT DEVELOPMENTS AND PARTNERSHIPS	248
PanC-Dx	249
TransPLEX	249
Abbott and Merck Partnership	250
AltheaDx and Compendia Bioscience Partnership	250
GE Healthcare and Early Diagnosis	250
GE Investment in NanoString Technologies	251
Aeterna Zentaris and Ventana Partnership	251

<b>TOPIC</b>	<b>PAGE NO.</b>
MDxHealth and Pfizer Partnership	251
Palbociclib for Treatment of ER-Positive, HER2-Negative Advanced Stage Breast Cancer	252
FDA Priority Review of Roche's Pertuzumab	253
Two Drugs that Hit One Target Show Efficacy against Metastatic Breast Cancer	254
New Experimental Breast Cancer Drug Shows Promise	254
Bemaciclib for Treatment of Metastatic Breast Cancer	255
Perjeta Trial	255
I-SPY 2 Trial for Neratinib	256
BREAST CANCER DRUG AND DIAGNOSTIC PATENT LANDSCAPE	257
Recent Patent Expirations on Breast Cancer Drugs	257
Breast Cancer Predictive Diagnostic Patents	257
RECENT PATENT-RELATED ACTIVITY	258
Gene Ownership and Patent Issues	258
Phigenix Breast Cancer Patent	259
Galena Biopharma's NeuVax Patent	259
Hospira and Roche's Herceptin Patent	260
Other Breast Cancer Drugs	260
Ridaforolimus	260
Buparlisib	261
<i>TABLE 102 BUPARLISIB CLINICAL TRIALS</i>	261
Faslodex (Fulvestrant Injection)	261
Iniparib (Tivolza)	261
Xgeva (Denosumab)	261
Nexavar (Sorafenib)	262
Arimidex	262
Afinitor	262
<i>TABLE 103 AFINITOR PATENTS AND EXPIRY</i>	262
CONCLUSIONS	262
CHAPTER 11 BIBLIOGRAPHY	265

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)	9
TABLE 1 SEER SUMMARY STAGE SYSTEM FOR BREAST CANCER	12
TABLE 2 TYPES OF HORMONE THERAPY FOR BREAST CANCER	17
TABLE 3 BREAST CANCER STAGES	18
TABLE 4 BREAST CANCER GRADES	29
TABLE 5 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD	30
TABLE 6 TESTS USED TO EVALUATE DIFFERENT GENE SETS FOR BREAST CANCER TREATMENT	31
TABLE 7 BIOPSY AND SURGICAL SAMPLE TESTING TECHNIQUES	32
TABLE 8 HER2 TESTING AND VARIATIONS	34
TABLE 9 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN	41
TABLE 10 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (NO.%)	50
TABLE 11 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE	51
TABLE 12 APPROVED COMPANION DIAGNOSTICS FOR BREAST CANCER	52
TABLE 13 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE	63
TABLE 14 CLINICALLY RELEVANT BIOMARKERS	63
TABLE 15 FDA APPROVED CANCER DRUGS, 2014	71
TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	78
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS	78
TABLE 18 NEXT GENERATION BREAST CANCER TESTS	80
TABLE 19 DIAGNOSED CASES OF CANCER EXCLUDING NON-MELANOMA SKIN CANCER, 2012 (NO./%)	88
TABLE 20 MOST COMMONLY DIAGNOSED CANCERS GLOBALLY, 2012 (MILLIONS/%)	89
TABLE 21 AGE STANDARDIZED CANCER RATE PER 100,000 PEOPLE IN DEVELOPED AND LESS DEVELOPED COUNTRIES, 2012	91
TABLE 22 BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008 (THOUSANDS)	95
TABLE 23 BREAST CANCER INCIDENCE BY COUNTRY, 2012	97
TABLE 24 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019	99
TABLE 25 NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 AND 2012	102
TABLE 26 ESTIMATED GLOBAL BREAST CANCER INCIDENCE RATES FOR ALL AGES, 2012	104
TABLE 27 POTENTIAL REDUCTION IN DEATHS DUE TO BREAST CANCER FROM EARLY DETECTION, U.K. AND U.S. (CASES PER DAY)	104
TABLE 28 U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019 (NO.)	108
TABLE 29 U.S. NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011 (THOUSANDS)	109
TABLE 30 U.S. ESTIMATED BREAST CANCER INCIDENCE AND DEATHS, 2012 (THOUSANDS)	110
TABLE 31 COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN IN THE U.S., 2012	110
TABLE 32 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY BY RACE, 2006-2010 (INCIDENCE PER 100,000)	113
TABLE 33 U.S. ESTIMATED BREAST CANCER INCIDENCE (2004-2008) AND MORTALITY (2003-2007) FOR ASIAN WOMEN (PER 100,000)	113

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 34 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY FOR HISPANIC/LATINA WOMEN, 2006-2010 (PER 100,000)	114
TABLE 35 U.S. ESTIMATED BREAST CANCER INCIDENCE AND MORTALITY IN NATIVE AMERICAN WOMEN COMPARED WITH OTHER RACES, 2006-2010 (PER 100,000)	115
TABLE 36 BREAST CANCER RISK BY AGE	116
TABLE 37 RELATIVE CANCER SURVIVAL IN WOMEN IN THE U.S. (%)	118
TABLE 38 ESTIMATED CANADIAN BREAST CANCER STATISTICS, 2014	120
TABLE 39 CANADIAN ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010	121
TABLE 40 ESTIMATED NEW BREAST CANCER CASES, DEATHS FROM CANCER AND AGE-STANDARDIZED RATES PER 100,000 IN EUROPE, 2012 (THOUSANDS)	122
TABLE 41 BREAST CANCER STATISTICS IN THE U.K. AND IRELAND	123
TABLE 42 U.K. AGE STANDARDIZED BREAST CANCER INCIDENCE RATES, 2011 (PER 100,000)	124
TABLE 43 U.K. AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES, 2008 (PER 100,000.)	125
TABLE 44 ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K., 2008-2019	126
TABLE 45 GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019	127
TABLE 46 PROJECTED NEW CASES OF BREAST CANCER IN AUSTRALIA AND NEW ZEALAND, 2012	128
TABLE 47 ASIAN ESTIMATED BREAST CANCER INCIDENCE, 2012	129
TABLE 48 CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019	130
TABLE 49 INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-2019 (THOUSANDS)	133
TABLE 50 JAPANESE ESTIMATED BREAST CANCER INCIDENCE, 2010-2012 (THOUSANDS)	134
TABLE 51 FIVE-YEAR SURVIVAL RATES FOR BREAST CANCER (%)	135
TABLE 52 SELECTED BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE (%)	136
TABLE 53 U.S. PERCENTAGE OF BREAST CANCER CASES AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2004-2010 (%)	139
TABLE 54 ONCOLOGY DRUGS APPROVED BY THE FDA, 2014	143
TABLE 55 ONCOLOGY DRUGS APPROVED BY THE FDA, 2013	143
TABLE 56 ONCOLOGY DRUGS APPROVED BY THE FDA, 2012	144
TABLE 57 ONCOLOGY DRUGS APPROVED BY THE FDA, 2011	145
TABLE 58 ONCOLOGY DRUGS APPROVED BY THE FDA, 2010	145
TABLE 59 DRUGS APPROVED TO TREAT BREAST CANCER	151
TABLE 60 HORMONE THERAPY FOR BREAST CANCER	153
TABLE 61 AROMATASE INHIBITORS FOR TREATING BREAST CANCER	153
TABLE 62 CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER	153
TABLE 63 TARGETED THERAPEUTICS FOR BREAST CANCER	155
TABLE 64 GLOBAL MARKET FOR TARGETED CANCER DRUGS, 2008-2019 (\$ MILLIONS)	163
TABLE 65 GLOBAL PHARMACEUTICAL SALES, THROUGH 2019 (\$ MILLIONS)	165
TABLE 66 BREAST CANCER THERAPY SALES, THROUGH 2019 (\$ MILLIONS)	170
TABLE 67 BREAST CANCER DRUG MARKET, 2014 AND 2019 (\$ MILLIONS)	170
TABLE 68 PERJETA DRUG SALES, 2012-2014 (\$ THOUSANDS)	172
TABLE 69 KADCYLA DRUG SALES, 2013 AND 2014 (\$ THOUSANDS)	173
TABLE 70 HERCEPTIN DRUG SALES, 2012-2014 (\$ THOUSANDS)	173
TABLE 71 BREAST CANCER TARGETED THERAPIES, 2010-2014 (\$ MILLIONS)	174
TABLE 72 ROCHE PHARMACEUTICALS DIVISION SALES, 2012-2013 (\$ MILLIONS)	175

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 73 ROCHE SALES COMPARED WITH THE GLOBAL MARKET, 2010 (\$ MILLIONS/%)	176
TABLE 74 XELODA SALES, 2010 AND 2011 (\$ MILLIONS)	176
TABLE 75 ROCHE SALES VERSUS THE GLOBAL MARKET, 2011 (\$ MILLIONS/%)	177
TABLE 76 EXPECTED SALES FOR PERTUZUMAB, 2016	178
TABLE 77 AUSTRALIA: CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)	179
TABLE 78 AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)	180
TABLE 79 BREAST CANCER MONOCLONAL ANTIBODY MARKET, 2014 AND 2019 (\$ MILLIONS)	185
TABLE 80 ANNUALIZED MEAN NET COST OF BREAST CANCER CARE, 2010 (\$ PER PATIENT)	186
TABLE 81 U.S. PREDICTIVE PERSONALIZED MEDICINE MARKET, 2013 AND 2019 (\$ MILLIONS)	187
TABLE 82 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2019 (\$ MILLIONS)	188
TABLE 83 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)	190
TABLE 84 GLOBAL IVD MARKET, THROUGH 2019 (\$ MILLIONS)	192
TABLE 85 BREAST CANCER DIAGNOSTIC TESTS	192
TABLE 86 BREAST CANCER GENETIC TESTS	196
TABLE 87 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2012-2019	197
TABLE 88 GLOBAL INCIDENCE OF ER-POSITIVE BREAST CANCER, 2012-2019	198
TABLE 89 BREAST CANCER DIAGNOSTIC TEST COSTS	205
TABLE 90 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)	206
TABLE 91 IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2019 (\$ MILLIONS)	207
TABLE 92 FDA-APPROVED COMMERCIAL IHC KITS	208
TABLE 93 FDA-APPROVED FISH ANALYSIS TESTS	210
TABLE 94 ONCOLOGY BREAST CANCER DRUG SALES BY REGION, 2013 (\$ MILLIONS)	212
TABLE 95 ROCHE DIAGNOSTIC SALES, 2012 AND 2013 (\$ MILLIONS)	213
TABLE 96 ROCHE SALES BY DIVISION, 2010 (\$ MILLIONS)	213
TABLE 97 CURRENTLY MARKETED ROCHE COMPANION DIAGNOSTICS	214
TABLE 98 GENOMIC ASSAY MARKET LEADERS	215
TABLE 99 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019 (\$ MILLIONS)	216
TABLE 100 ONCOTYPE DX SALES, THROUGH 2019 (\$ MILLIONS)	218
TABLE 101 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2019 (\$ MILLIONS)	220
TABLE 102 BUPARLISIB CLINICAL TRIALS	261
TABLE 103 AFINITOR PATENTS AND EXPIRY	262



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2012-2019 (\$ MILLIONS)	9
FIGURE 1 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008 (THOUSANDS)	96
FIGURE 2 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2011-2019 (NO. OF CASES)	99
FIGURE 3 U.S. ESTIMATED BREAST CANCER INCIDENCE, BY GENDER, 2010-2019 (NO.)	108
FIGURE 4 ESTIMATED INCIDENCE OF BREAST CANCER IN THE U.K., 2008-2019 (THOUSANDS)	126
FIGURE 5 GERMAN ESTIMATED BREAST CANCER INCIDENCE, 2010-2019	127
FIGURE 6 CHINESE ESTIMATED BREAST CANCER INCIDENCE, 2008-2019	130
FIGURE 7 INDIAN ESTIMATED BREAST CANCER INCIDENCE, 2008-(NO. OF CASES)2019	133
FIGURE 8 GLOBAL PHARMACEUTICAL SALES, 2010-2019 (\$ MILLIONS)	165
FIGURE 9 BREAST CANCER THERAPY SALES, 2010-2019 (\$ MILLIONS)	170
FIGURE 10 BREAST CANCER DRUG MARKET, 2014 AND 2019 (\$ MILLIONS)	170
FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2013 AND 2019 (\$ MILLIONS)	187
FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2011-2019 (\$ MILLIONS)	188
FIGURE 13 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2012-2019 (\$ MILLIONS)	206
FIGURE 14 IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2012-2019 (\$ MILLIONS)	208
FIGURE 15 GENOMIC TESTING MARKET FOR BREAST CANCER, 2012-2019 (\$ MILLIONS)	216
FIGURE 16 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2012-2019 (\$ MILLIONS)	221